{"acute myeloid leukaemia": 5.1, "anaemia": 5.28, "ascites": 3.02, "bone marrow failure": 4.3, "cholinergic syndrome": 46.63, "colitis": 5.31, "colorectal cancer metastatic": 100.87, "conjunctivitis": 2.5, "constipation": 2.62, "decreased appetite": 2.78, "dehydration": 2.64, "dermatitis acneiform": 36.98, "diarrhoea": 5.4, "disease progression": 9.4, "dry skin": 4.76, "dysarthria": 6.92, "ejection fraction decreased": 4.45, "febrile neutropenia": 16.55, "gastrointestinal toxicity": 50.03, "general physical health deterioration": 2.74, "haematotoxicity": 34.83, "hyperammonaemia": 8.8, "hyperbilirubinaemia": 3.08, "hypertransaminasaemia": 9.6, "hypomagnesaemia": 17.51, "interstitial lung disease": 2.51, "intestinal obstruction": 3.77, "leukopenia": 6.34, "maligt neoplasm progression": 4.03, "metastases to bone": 3.92, "metastases to liver": 14.93, "metastases to lung": 11.38, "metastases to lymph nodes": 8.33, "metastases to peritoneum": 29.66, "mucosal inflammation": 20.44, "myelodysplastic syndrome": 3.52, "myelosuppression": 7.87, "neoplasm progression": 3.08, "neuropathy peripheral": 9.01, "neurotoxicity": 15.55, "neutropenia": 23.61, "neutrophil count decreased": 8.6, "palmar-plantar erythrodysaesthesia syndrome": 2.01, "pancreatic carcinoma metastatic": 14.28, "pancytopenia": 2.61, "paronychia": 29.59, "peripheral sensory neuropathy": 18.66, "polyneuropathy": 3.33, "proteinuria": 4.98, "rash pustular": 6.26, "skin toxicity": 43.3, "stomatitis": 11.7, "therapeutic product effect incomplete": 2.55, "therapeutic response decreased": 2.04, "therapy partial responder": 19.36, "thrombocytopenia": 7.96, "vomiting": 2.57, "white blood cell count decreased": 3.77}